Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines

被引:32
作者
Nakatsu, Noriyuki [1 ,2 ]
Nakamura, Tomoki [1 ,3 ]
Yamazaki, Kanami [1 ]
Sadahiro, Soutaro [3 ]
Makuuchi, Hiroyasu [3 ]
Kanno, Jun [2 ]
Yamori, Takao [1 ]
机构
[1] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Ctr Canc Chemotherapy, Div Mol Pharmacol,Koto Ku, Tokyo 170, Japan
[2] Natl Inst Hlth Sci, Biol Safety Res Ctr, Div Cellular & Mol Toxicol, Setagaya Ku, Tokyo 158, Japan
[3] Tokai Univ, Sch Med, Dept Surg 2, Isehara, Kanagawa 25911, Japan
关键词
D O I
10.1124/mol.107.038836
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We previously established a panel of human cancer cell lines, JFCR39, coupled to an anticancer drug activity database; this panel is comparable with the NCI60 panel developed by the National Cancer Institute. The JFCR39 system can be used to predict the molecular targets or evaluate the action mechanisms of the test compounds by comparing their cell growth inhibition profiles (i. e., fingerprints) with those of the standard anticancer drugs using the COMPARE program. In this study, we used this drug activity database-coupled JFCR39 system to evaluate the action mechanisms of various chemical compounds, including toxic chemicals, agricultural chemicals, drugs, and synthetic intermediates. Fingerprints of 130 chemicals were determined and stored in the database. Sixty-nine of 130 chemicals (similar to 60%) satisfied our criteria for the further analysis and were classified by cluster analysis of the fingerprints of these chemicals and several standard anticancer drugs into the following three clusters: 1) anticancer drugs, 2) chemicals that shared similar action mechanisms (for example, ouabain and digoxin), and 3) chemicals whose action mechanisms were unknown. These results suggested that chemicals belonging to a cluster (i. e., a cluster of toxic chemicals, a cluster of anticancer drugs, etc.) shared similar action mechanism. In summary, the JFCR39 system can classify chemicals based on their fingerprints, even when their action mechanisms are unknown, and it is highly probable that the chemicals within a cluster share common action mechanisms.
引用
收藏
页码:1171 / 1180
页数:10
相关论文
共 26 条
[1]   Rapid communication - A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteins [J].
Akashi, Tetsuyuki ;
Yamori, Takao .
PROTEOMICS, 2007, 7 (14) :2350-2354
[2]   Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer [J].
Akashi, Tetsuyuki ;
Nishimura, Yumiko ;
Wakatabe, Rumi ;
Shiwa, Mieko ;
Yamori, Takao .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (02) :514-521
[3]   RETINOIC ACID AND SYNTHETIC ANALOGS DIFFERENTIALLY ACTIVATE RETINOIC ACID RECEPTOR DEPENDENT TRANSCRIPTION [J].
ASTROM, A ;
PETTERSSON, U ;
KRUST, A ;
CHAMBON, P ;
VOORHEES, JJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (01) :339-345
[4]   An evaluation of thiram toxicity on cultured human skin fibroblasts [J].
Cereser, C ;
Boget, S ;
Parvaz, P ;
Revol, A .
TOXICOLOGY, 2001, 162 (02) :89-101
[5]   Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin [J].
Chvalova, Katerina ;
Brabec, Viktor ;
Kasparkova, Jana .
NUCLEIC ACIDS RESEARCH, 2007, 35 (06) :1812-1821
[6]   Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines [J].
Dan, S ;
Shirakawa, M ;
Mukai, Y ;
Yoshida, Y ;
Yamazaki, K ;
Kawaguchi, T ;
Matsuura, M ;
Nakamura, Y ;
Yamori, T .
CANCER SCIENCE, 2003, 94 (12) :1074-1082
[7]  
Dan S, 2002, CANCER RES, V62, P1139
[8]  
HERSHBERGER LG, 1953, P SOC EXP BIOL MED, V83, P175
[9]   Structure, recognition, and processing of cisplatin-DNA adducts [J].
Jamieson, ER ;
Lippard, SJ .
CHEMICAL REVIEWS, 1999, 99 (09) :2467-2498
[10]   Phytoestrogen-low diet for endocrine disruptor studies [J].
Kanno, J ;
Kato, H ;
Iwata, T ;
Inoue, T .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2002, 50 (13) :3883-3885